News
You are here: Home » News

News and Events

2025
DATE
10 - 29
Dapagliflozin — Advanced Blood Sugar Control
Dapagliflozin is a modern SGLT2 inhibitor widely used for the treatment of type 2 diabetes mellitus. It works by blocking glucose reabsorption in the kidneys, promoting the excretion of glucose through urine, and thereby effectively lowering blood glucose levels.Clinical ApplicationsManagement of ty
Read More
2025
DATE
10 - 18
Ruiming Loxoprofen Sodium: Relief for Pain and Fever
Loxoprofen Sodium is a widely used nonsteroidal anti-inflammatory drug (NSAID), designed to relieve pain, inflammation, and fever. By selectively inhibiting cyclooxygenase enzymes (COX-1 and COX-2), Loxoprofen Sodium reduces the production of prostaglandins, the chemicals responsible for pain and in
Read More
2025
DATE
10 - 15
Propafenone Hydrochloride — Effective Antiarrhythmic Medication by Changzhou Ruiming Pharmaceutical
Propafenone Hydrochloride is a clinically proven antiarrhythmic drug widely used for the management of abnormal heart rhythms (arrhythmias), particularly those originating in the atria. By stabilizing the electrical activity of the heart, Propafenone Hydrochloride helps restore and maintain a normal
Read More
2025
DATE
10 - 07
A Targeted Tyrosine Kinase Inhibitor for Advanced Cancer Therapy
Intedanib is a next-generation tyrosine kinase inhibitor (TKI) designed to combat cancers driven by abnormal kinase activity, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). As a precision medicine, it works by selectively targeting the molecular pathways responsible
Read More
2025
DATE
09 - 23
Clinical Guidelines and Dosing Strategies for Mirogabalin Besylate
Mirogabalin besylate is an oral ligand of the α2δ subunit of voltage-gated calcium channels, primarily used for neuropathic pain such as diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). Its high receptor selectivity and favorable safety profile make it a valuable option for pai
Read More
2025
DATE
09 - 23
Mirogabalin Besylate: Market Outlook After Insurance Inclusion
Mirogabalin besylate is a novel oral drug targeting the α2δ subunit of voltage-gated calcium channels. It treats neuropathic pain, including diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). Compared to pregabalin, it offers better receptor selectivity, improved pharmacokinetics
Read More
2025
DATE
09 - 12
Levamlodipine Besylate and Endothelial Function Improvement
Levamlodipine besylate, a calcium channel blocker, is widely used to treat hypertension. Beyond lowering blood pressure, it can improve vascular endothelial function, which is crucial for cardiovascular health.Mechanism of ActionEnhances Nitric Oxide (NO) Production: Promotes vasodilation and reduce
Read More
2025
DATE
09 - 04
Efficacy of Levamlodipine Besylate in Treating Mild to Moderate Hypertension
Levamlodipine besylate is a calcium channel blocker widely prescribed for the management of hypertension and angina pectoris. By relaxing vascular smooth muscles, it reduces peripheral resistance, resulting in lower blood pressure and improved cardiac blood flow. This makes it particularly effective
Read More
2025
DATE
06 - 04
Global API Market Trends: Innovation and Supply Chain Resilience in Focus
The global Active Pharmaceutical Ingredient (API) market continues to experience robust growth, driven by innovation in drug development, increasing demand for generic medicines, and a renewed emphasis on supply chain resilience. According to recent industry data, the API sector is expected to surpa
Read More
2024
DATE
11 - 25
Changzhou Ruiming Pharmaceutical: Driven by scientific and technological innovation, it helps a new chapter in diabetes treatment
Under the severe challenge of diabetes as a global health problem, Changzhou Ruiming Pharmaceutical Co., LTD. (hereinafter referred to as "Ruiming Pharmaceutical") is gradually becoming a new force in the field of diabetes treatment with its profound accumulation and unremitting innovation in the fi
Read More
  • Total 2 pages  Go to Page
  • Go
Specializing in the development, production and sales of pharmaceutical raw materials and their intermediates.
  0519-85095533
+86 18261172629
 +86 18118380910             
  No. 1558 Longjiang Bei Road Chunjiang Town Xinbei District, Changzhou City, Jiangsu Province,China

QUICK LINKS

Solution

PRODUCT CATEGORY

Intermediates of Amlodipine Besylate
Copyright © 2024 Changzhou Ruiming Pharmaceutical Co., Ltd. All Rights Reserved. Sitemap
Contact Us